Principal Financial Group Inc. Increases Position in BridgeBio Pharma, Inc. $BBIO

Principal Financial Group Inc. lifted its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 1.2% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,330,415 shares of the company’s stock after purchasing an additional 16,112 shares during the period. Principal Financial Group Inc.’s holdings in BridgeBio Pharma were worth $98,797,000 as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in BBIO. Teachers Retirement System of The State of Kentucky increased its holdings in BridgeBio Pharma by 7.6% in the first quarter. Teachers Retirement System of The State of Kentucky now owns 30,343 shares of the company’s stock valued at $2,253,000 after buying an additional 2,132 shares in the last quarter. Citizens Financial Group Inc. RI purchased a new stake in shares of BridgeBio Pharma during the 1st quarter worth approximately $303,000. Fifth Third Bancorp acquired a new stake in shares of BridgeBio Pharma in the 1st quarter worth approximately $3,693,000. Hsbc Holdings PLC grew its holdings in shares of BridgeBio Pharma by 139.4% in the 1st quarter. Hsbc Holdings PLC now owns 32,708 shares of the company’s stock worth $2,431,000 after acquiring an additional 19,043 shares during the period. Finally, Sumitomo Mitsui Trust Group Inc. purchased a new position in BridgeBio Pharma in the 1st quarter valued at approximately $229,000. Hedge funds and other institutional investors own 99.85% of the company’s stock.

Insider Buying and Selling at BridgeBio Pharma

In related news, Director Andrea Ellis sold 17,167 shares of the company’s stock in a transaction that occurred on Thursday, July 9th. The shares were sold at an average price of $84.00, for a total transaction of $1,442,028.00. Following the transaction, the director owned 22,579 shares of the company’s stock, valued at approximately $1,896,636. This represents a 43.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Neil Kumar sold 40,000 shares of the firm’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $67.46, for a total transaction of $2,698,400.00. Following the sale, the chief executive officer owned 535,686 shares in the company, valued at approximately $36,137,377.56. This trade represents a 6.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 432,117 shares of company stock valued at $32,633,740. Corporate insiders own 14.23% of the company’s stock.

Trending Headlines about BridgeBio Pharma

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and $120 price target on BridgeBio Pharma, while raising several longer-term earnings estimates, including FY2027 EPS to $2.19. This supports the view that analysts still see substantial upside potential. BridgeBio Pharma analyst report
• Positive Sentiment: HC Wainwright also increased its Q4 2026, Q2 2027, Q3 2027, and Q4 2027 EPS forecasts, suggesting improving expectations for BridgeBio’s profitability over time. BridgeBio Pharma analyst report
• Neutral Sentiment: The analyst slightly lowered near-term estimates for Q3 2026 and Q1 2027 EPS and trimmed FY2026 EPS, reflecting some caution on the company’s shorter-term earnings trajectory. BridgeBio Pharma analyst report
• Negative Sentiment: Director Andrea Ellis sold 17,167 shares worth about $1.44 million, a disclosure that can weigh on investor sentiment even though the trade was made under a pre-arranged 10b5-1 plan. Insider selling article

BridgeBio Pharma Stock Down 1.7%

BBIO opened at $82.66 on Thursday. The firm has a market cap of $16.19 billion, a P/E ratio of -22.10 and a beta of 0.95. BridgeBio Pharma, Inc. has a 52 week low of $42.09 and a 52 week high of $93.42. The business’s fifty day simple moving average is $70.60 and its 200 day simple moving average is $72.22.

BridgeBio Pharma (NASDAQ:BBIO) last announced its earnings results on Thursday, May 7th. The company reported ($0.84) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.14). The company had revenue of $194.51 million for the quarter, compared to analysts’ expectations of $178.07 million. The company’s revenue was up 66.8% compared to the same quarter last year. During the same period last year, the firm earned ($0.88) earnings per share. As a group, equities analysts expect that BridgeBio Pharma, Inc. will post -2.29 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on the company. Weiss Ratings reiterated a “sell (d)” rating on shares of BridgeBio Pharma in a research report on Friday, May 15th. Citigroup initiated coverage on BridgeBio Pharma in a research report on Tuesday, May 19th. They issued a “neutral” rating and a $82.00 price target for the company. Morgan Stanley lifted their price target on BridgeBio Pharma from $94.00 to $98.00 and gave the stock an “overweight” rating in a research note on Thursday, May 28th. Raymond James Financial cut shares of BridgeBio Pharma from an “outperform” rating to a “market perform” rating in a research note on Tuesday, May 26th. Finally, Mizuho dropped their target price on shares of BridgeBio Pharma from $106.00 to $96.00 and set an “outperform” rating for the company in a report on Tuesday, June 16th. Twenty analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, BridgeBio Pharma currently has a consensus rating of “Moderate Buy” and a consensus price target of $94.63.

BridgeBio Pharma Profile

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio’s pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.